Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
Open Access
- 26 February 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (7) , 1214-1226
Abstract
Objective: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune‐mediated vasculopathy. This study was undertaken to 1) identify inflammation/endothelial dysfunction–related biomarker profiles reflecting disease severity at diagnosis, and 2) establish whether such biomarker profiles could be used for predicting the response to treatment in patients with juvenile DM.Methods: In total, 39 biomarkers related to activation of endothelial cells, endothelial dysfunction, and inflammation were measured using multiplex technology in serum samples from treatment‐naive patients with juvenile DM from 2 independent cohorts (n = 30 and n = 29). Data were analyzed by unsupervised hierarchical clustering, nonparametric tests with correction for multiple comparisons, and Kaplan‐Meier tests with Cox proportional hazards models for analysis of treatment duration. Myositis‐specific antibodies (MSAs) were measured in the patients’ serum using line blot assays.Results: Severe vasculopathy in patients with juvenile DM was associated with low serum levels of intercellular adhesion molecule 1 (Spearman's rho [rs] = 0.465, P = 0.0111) and high serum levels of endoglin (rs = −0.67, P < 0.0001). In the discovery cohort, unsupervised hierarchical clustering analysis of the biomarker profiles yielded 2 distinct patient clusters, of which the smaller cluster (cluster 1; n = 8) exhibited high serum levels of CXCL13, CCL19, galectin‐9, CXCL10, tumor necrosis factor receptor type II (TNFRII), and galectin‐1 (false discovery rate P < 0.05 versus cluster 2). In the validation cohort, correlations between the serum levels of galectin‐9, CXCL10, TNFRII, and galectin‐1 and the severity of global disease activity were confirmed (rs = 0.40–0.52, P < 0.05). Stratification of patients according to the 4 confirmed biomarkers identified a cluster of patients with severe symptoms (comprising 64.7% of patients) who were considered at high risk of requiring more intensive treatment in the first 3 months after diagnosis (P = 0.0437 versus other cluster). Moreover, high serum levels of galectin‐9, CXCL10, and TNFRII were predictive of a longer total treatment duration (P < 0.05). The biomarker‐based clusters were not evidently correlated with patients’ MSA serotypes.Conclusion: Results of this study confirm the heterogeneity of new‐onset juvenile DM based on serum biomarker profiles. Patients with high serum levels of galectin‐9, CXCL10, TNFRII, and galectin‐1 may respond suboptimally to conventional treatment, and may therefore benefit from more intensive monitoring and/or treatment.Keywords
Funding Information
- Innovatiefonds Zorgverzekeraars
This publication has 50 references indexed in Scilit:
- Soluble Adhesion Molecules Correlate with Surface Expression in an In Vitro Model of Endothelial ActivationBasic & Clinical Pharmacology & Toxicology, 2013
- Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositisRheumatology, 2010
- Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositisArthritis & Rheumatism, 2008
- Persistent association of nailfold capillaroscopy changes and skin involvement over thirty‐six months with duration of untreated disease in patients with juvenile dermatomyositisArthritis & Rheumatism, 2008
- Inhibitory control of endothelial galectin‐1 on in vitro and in vivo lymphocyte traffickingThe FASEB Journal, 2007
- MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvementClinical Immunology, 2006
- Galectin‐1 Induces Skeletal Muscle Differentiation in Human Fetal Mesenchymal Stem Cells and Increases Muscle RegenerationStem Cells, 2006
- Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migrationLaboratory Investigation, 2006
- Increased Plasma Thrombospondin-1 (TSP-1) Levels Are Associated with the TNFα-308A Allele in Children with Juvenile DermatomyositisClinical Immunology, 2002
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986